ABVC

About ABVC

ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on the development of drugs and medical devices derived from plants. The Company develops its pipeline by tracking medical discoveries or medical device technologies in research institutions in the Asia-Pacific region. It has a pipeline of six drugs and one medical device under development. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1701, ABV-1519, ABV-1703 and ABV-1703. ABV-1504 is a botanical reuptake inhibitor that targets norepinephrine to treat major depressive disorder (MDD). It is developing ABV-1505 for treating attention deficit hyperactivity disorder (ADHD). It has developed ABV-1601 for treating depression in cancer patients. ABV-1701 is a vitreous substitute for vitrectomy. Its ABV-1702 is used to treat myelodysplastic syndrome (MDS). ABV-1703 is a drug for advanced, inoperable, or metastatic pancreatic cancer. Its ABV-1519 is used for the treatment of non-small cell lung cancer.